Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions

Trial Profile

Randomized, Open Label, 2-way Crossover, Single Dose Bioequivalence Study of Paroxetine IR Tablets Manufactured in GSKT and Mississauga Sites in Healthy Chinese Participants Under Fasting and Fed Conditions

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2018

At a glance

  • Drugs Paroxetine (Primary)
  • Indications Depressive disorders; Generalised anxiety disorder; Major depressive disorder; Obsessive-compulsive disorders; Panic disorder; Post-traumatic stress disorders; Premenstrual dysphoric disorder; Social phobia
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 13 Jul 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 30 May 2018 Planned number of patients changed from 96 to 80.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top